Eirion Therapeutics Announces Initiation of First-in-Human Clinical Trial Evaluating Topical ET-02 for the Treatment of Androgenic Alopecia

Excerpt from the Press Release:

WOBURN, Mass., July 1, 2024 /PRNewswire/ — Eirion Therapeutics Inc. announced today that the first participant has been enrolled in a Phase 1 clinical trial to evaluate the safety of the patented topical pharmaceutical ET-02 for the treatment of androgenic alopecia (age-related hair loss). This double-blind, placebo-controlled study is designed to determine the safety of ET-02 for once daily treatment over 28 days. The study is expected to recruit approximately 24 subjects at three investigation centers in the United States.

ET-02 has a novel mechanism of action which targets returning hair follicle stem cells that have become defective and / or inactive in men suffering from age-related hair loss to normal activity and function. Hair follicle stem cells are known to be the “master control switches” for hair growth. By returning stem cells to normal activity and function, the expectation is that hair can be grown normally again. Because ET-02 directly addresses what the Company believes is the fundamental cause of androgenic alopecia, the Company expects this new treatment has the potential to be significantly more effective than existing treatments which have no known direct impact on hair follicle stem cells.

“Given its postulated mechanism of action, ET-02 represents a potentially substantial advancement over commercially available pharmaceuticals for the treatment of androgenic alopecia,” said Jerry Shapiro, MD, a leading expert on the treatment of hair loss and Professor of Dermatology at New York University Grossman School of Medicine. “This Phase 1 safety study is an important first step in evaluating ET-02. Assuming all goes well, this study will lead to a Phase 2 study evaluating ET-02’s efficacy.”

Click the button below to read the entire Press Release:

Continue Reading The Press Release